US Patent Issued to MAPI PHARMA on July 1 for "Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate" (Israeli Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,343,371, issued on July 1, was assigned to MAPI PHARMA LTD. (Ness Ziona, Israel).

"Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate" was invented by Uri Danon (Tel Aviv, Israel), Nadav Bleich Kimelman (Tel Aviv, Israel), Laura Popper (Tel Aviv, Israel) and Ehud Marom (Tel Aviv, Israel).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administer...